{"id":4356,"date":"2026-10-12T08:32:57","date_gmt":"2026-10-12T08:32:57","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4356"},"modified":"2026-10-12T08:32:57","modified_gmt":"2026-10-12T08:32:57","slug":"%d8%b4%d8%b1%d8%ad-%d8%a5%d8%ad%d8%b5%d8%a7%d8%a1%d8%a7%d8%aa-%d8%a7%d9%84%d9%85%d8%b5%d9%84-%d9%84%d9%80-motsc-pcos","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/motsc-pcos-serum-statistics-explained\/","title":{"rendered":"MOTS-c \u0641\u064a \u0645\u062a\u0644\u0627\u0632\u0645\u0629 \u062a\u0643\u064a\u0633 \u0627\u0644\u0645\u0628\u0627\u064a\u0636 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0627\u0647\u0642\u0627\u062a: \u0644\u0645\u0627\u0630\u0627 \u0644\u0627 \u064a\u064f\u0639\u062f \u0627\u0644\u0645\u062a\u0648\u0633\u0637 \u0627\u0644\u0623\u0639\u0644\u0649 \u0641\u0631\u0642\u064b\u0627 \u0645\u0624\u0643\u062f\u064b\u0627"},"content":{"rendered":"
\n
\"Thematic
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

One study measured MOTS-c in adolescents with polycystic ovary syndrome. The results appeared to show a small difference, but this was not confirmed statistically. This kind of result is still worth reading, because it helps us judge whether a biomarker can really be used to distinguish populations.<\/p>\n

\n

In this study, participants were not given MOTS-c supplements<\/h2>\n

The authors compared 121 participants with polycystic ovary syndrome aged 12 to 18 with 125 healthy controls, measured serum MOTS-c, and checked one related gene locus.<\/p>\n

Serum can be understood as the portion of blood used for testing after processing. Measuring a peptide already present in the body and additionally using that peptide are two different research questions. This is an observational study.<\/p>\n<\/section>\n

\n

A slightly higher average does not necessarily mean a stable difference<\/h2>\n

In the study, the patient group had a higher average MOTS-c level, but the p value for the difference between groups was 0.059, which did not meet the common statistical significance standard used in the study.[1]<\/a><\/p>\n

An average is only the center position of two groups of data; you also need to look at how widely each person's data is spread. If the two groups' values overlap a lot, saying the populations can be distinguished based only on averages can easily lead to misjudgment.<\/p>\n<\/section>\n

\n

A p value is not "how likely it is to be effective"<\/h2>\n

A p value describes the extent to which current or more extreme data would be observed under a specific no-difference assumption and statistical model. It is not the probability that some material is effective, nor the probability that a patient has the disease.[1]<\/a><\/p>\n

0.059 also cannot simply be translated as "just short of proving effectiveness." A more appropriate approach is to combine the size of the difference, the range of uncertainty, and other studies to judge whether further testing is worthwhile.<\/p>\n<\/section>\n

\n

What else did genetic testing provide?<\/h2>\n

The study examined the m.1382A>C locus, but all participants had the same A\/A genotype. Since there was no other genotype in the sample, it is difficult to compare the effects of different genotypes in this group of people.<\/p>\n

In addition, MOTS-c did not show a clear association with body size or metabolic indicators. This suggests that under the conditions of this study, it did not become a highly discriminative indicator; it does not mean that all possibilities at other ages or disease stages are ruled out.<\/p>\n<\/section>\n

\n

If it were to be made into a testing indicator, what is still missing?<\/h2>\n

Repeated studies in different populations, stable testing methods, and evaluation of sensitivity and specificity are needed: it should both find the people who should be identified and avoid misjudging too many healthy people.<\/p>\n

This paper did not prove that MOTS-c can diagnose polycystic ovary syndrome, and it certainly did not study the therapeutic effects of MOTS-c supplementation. Its value is that it tested a hypothesis and provided results that do not yet support strong conclusions.<\/p>\n<\/section>\n

\n

If a test value is elevated, why does that not necessarily mean it needs to be lowered?<\/h2>\n

An elevation may be a cause, may be the body's response, or may change together with other factors. Only after understanding why it changes can we discuss whether intervention is warranted; we cannot decide to supplement or inhibit just because we see a high or low value.<\/p>\n

A one-time cross-sectional comparison is only a snapshot in time. Future work can track changes in the same person and verify findings in independent populations; even if a stable association is found, treatment trials still need to be done separately.<\/p>\n<\/section>\n